Wealthfront Advisers LLC Purchases 13,097 Shares of Zoetis Inc. $ZTS

Wealthfront Advisers LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 54.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,220 shares of the company’s stock after acquiring an additional 13,097 shares during the period. Wealthfront Advisers LLC’s holdings in Zoetis were worth $5,446,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Halbert Hargrove Global Advisors LLC grew its holdings in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the last quarter. NewSquare Capital LLC lifted its stake in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the last quarter. Financial Consulate Inc. purchased a new stake in Zoetis during the third quarter valued at about $39,000. SJS Investment Consulting Inc. grew its stake in shares of Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares during the last quarter. Finally, TruNorth Capital Management LLC bought a new position in shares of Zoetis during the third quarter valued at about $42,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of ZTS stock opened at $125.58 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00. The firm has a market cap of $55.34 billion, a P/E ratio of 21.14, a P/E/G ratio of 2.22 and a beta of 0.96. The business’s 50 day moving average price is $124.26 and its 200-day moving average price is $135.72.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.69%.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Q4 results beat consensus — adjusted EPS $1.48 vs. $1.40 est. and revenue $2.39B vs. $2.36B est.; the company raised FY‑2026 guidance to $7.00–$7.10 EPS and $9.8–$10.0B revenue, above consensus, supporting upside on earnings power and margin profile. Zoetis forecasts strong 2026 profit
• Positive Sentiment: High profitability metrics — Zoetis reported a robust net margin (~28%) and very high return on equity (~57%), which underscores cash-generation ability and supports valuation multiples. MarketBeat Q4 summary
• Neutral Sentiment: Full earnings call transcript and slide deck are available — management provided detail on geographic and product-line performance that investors will parse for forward visibility and execution risk. Earnings call transcript (Yahoo)
• Negative Sentiment: Analysts flagged weakening trends in key segments and questioned the path to sustained growth — concerns center on segment-specific slides that could make it harder to deliver the raised guidance without margin or mix improvements. Analysts question Zoetis’ pathway to growth (Benzinga)
• Negative Sentiment: Market commentary highlights topline pressure in the U.S. and execution risk on growth, which prompted some selling despite the beat and raised targets. Zoetis slips as outlook shows pressure (Seeking Alpha)
• Negative Sentiment: Popular-press coverage frames the reaction as “in the doghouse” — sentiment pieces emphasize that a beat alone may not overcome visible near‑term softness in certain product lines. MSN: Zoetis in the doghouse

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ZTS. Barclays started coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. Stifel Nicolaus lowered their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. HSBC set a $140.00 price objective on Zoetis in a research note on Wednesday, December 10th. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.